HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

<p>Abstract</p> <p>Background</p> <p>HER2 and TOP2A parameters (gene status, mRNA and protein expression) have individually been associated with the outcome of patients treated with anthracyclines. The aim of this study was to comprehensively evaluate the prognostic/pre...

Full description

Bibliographic Details
Main Authors: Fountzilas George, Valavanis Christos, Kotoula Vassiliki, Eleftheraki Anastasia G, Kalogeras Konstantine T, Tzaida Olympia, Batistatou Anna, Kronenwett Ralf, Wirtz Ralph M, Bobos Mattheos, Timotheadou Eleni, Soupos Nikolaos, Pentheroudakis George, Gogas Helen, Vlachodimitropoulos Dimitrios, Polychronidou Genovefa, Aravantinos Gerasimos, Koutras Angelos, Christodoulou Christos, Pectasides Dimitrios, Arapantoni Petroula
Format: Article
Language:English
Published: BMC 2012-01-01
Series:Journal of Translational Medicine
Subjects:
HER2
TOP2A
gene amplification
CISH
mRNA expression
early breast cancer
randomized study
anthracyclines
taxanes
Online Access:http://www.translational-medicine.com/content/10/1/10

Internet

http://www.translational-medicine.com/content/10/1/10

Similar Items